Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11426008 | 0.87 | TSHR (0.62) | TSHRTP53TDP1PPARDACHE | |
| SCHEMBL1486811 | 0.81 | TSHR (0.43) | TSHRTP53TDP1PPARD | |
| SCHEMBL7671005 | 0.78 | MEN1 (0.39) | TSHRTP53TDP1MEN1KMT2A | |
| SCHEMBL8062937 | 0.74 | TSHR (0.48) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL388425 | 0.73 | — | — | |
| SCHEMBL575185 | 0.73 | TSHR (0.71) | TSHRTP53TDP1PPARDACHE | |
| SCHEMBL8858060 | 0.71 | TSHR (0.50) | TSHRTP53TDP1PPARD | |
| SCHEMBL6966905 | 0.71 | — | — | |
| SCHEMBL20261798 | 0.71 | TSHR (0.67) | TSHRTP53TDP1PPARDACHE | |
| Ammonia Solution, Strong SCHEMBL9049883 | 0.71 | TSHR (0.67) | TSHRTP53TDP1PPARDACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2533344-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, ELECTROCHEMICAL ELEMENT USING SAME, AND ALKYNYL COMPOUND USED THEREFOR | Ube Industries, Ltd. (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-20060116400-A1 | Oxazolidinone and/or isoxazoline derivatives as antibacterial agents | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | US | disclosed |
| EP-0641800-B1 | Lactol derivatives as inhibitors of cathepsin L | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-01-16 | — | — | EP | disclosed |
| CN-1071751-C | Reversible protease inhibitors | ARRIS PHARM CORP (US) | 2001-09-26 | — | — | CN | disclosed |
| CN-1184472-A | Reversible protease inhibitors | ARRIS PHARM CORP (US) | 1998-06-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116400-A1 | Oxazolidinone and/or isoxazoline derivatives as antibacterial agents | NR0B2, NR0B1, HRH2 | TSHR 840/4885TP53 4851/4885TDP1 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.